In the last trading session, 2.69 million shares of the FibroGen Inc (NASDAQ:FGEN) were traded, and its beta was 0.82. Most recently the company’s share price was $0.34, and it changed around -$0.07 or -15.59% from the last close, which brings the market valuation of the company to $29.09M. FGEN currently trades at a discount to its 52-week high of $2.93, offering almost -761.76% off that amount. The share price’s 52-week low was $0.18, which indicates that the current value has risen by an impressive 47.06% since then. We note from FibroGen Inc’s average daily trading volume that its 10-day average is 0.92 million shares, with the 3-month average coming to 1.15 million.
FibroGen Inc stock received a consensus recommendation rating of Hold, based on a mean score of 4.00. If we narrow it down even further, the data shows that 0 out of 2 analysts rate the stock as a Sell; another 0 rate it as Overweight. Among the rest, 1 recommended FGEN as a Hold, whereas 0 deemed it a Buy, and 1 rated it as Underweight. FibroGen Inc is expected to report earnings per share of -0.2 for the current quarter.
FibroGen Inc (NASDAQ:FGEN) trade information
Instantly FGEN has showed a red trend with a performance of -15.59% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 0.4300 on recent trading dayincreased the stock’s daily price by 20.93%. The company’s shares are currently down -61.40% year-to-date, but still down -19.45% over the last five days. On the other hand, FibroGen Inc (NASDAQ:FGEN) is 10.21% up in the 30-day period. We can see from the shorts that 4.32 million shares have been sold at a short interest cover period of 3.27 day(s).
The consensus price target as assigned by Wall Street analysts is $28, which translates to bulls needing to increase their stock price by 98.79% from its current value. Analyst projections state that FGEN is forecast to be at a low of $28 and a high of $28.
FibroGen Inc (FGEN) estimates and forecasts
FibroGen Inc share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -68.90 percent over the past six months and at a 67.79% annual growth rate that is well above the industry average of 16.80%. The year-over-year growth rate is expected to be 17.20%, up from the previous year.
Consensus estimates provided by 2 financial analysts predict the company will bring in an average of 20.23M in revenue for the current quarter. 1 analysts expect FibroGen Inc to make 39.43M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 27.14M and 55.9M respectively. Analysts predict that the company’s current quarter sales will drop, forecast at -25.47%. Forecasts for the next quarter put sales growth at -29.47%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -23.23%.
FGEN Dividends
FibroGen Inc’s next quarterly earnings report is expected to be released in January.
FibroGen Inc (NASDAQ:FGEN)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 0.85% of FibroGen Inc shares, and 55.04% of them are in the hands of institutional investors. The stock currently has a share float of 55.51%. FibroGen Inc stock is held by 115.0 institutions, with PRIMECAP MANAGEMENT CO/CA/ being the largest institutional investor. By 2024-06-30, it held 13.7964% of the shares, which is about 13.66 million shares worth $12.19 million.
ARMISTICE CAPITAL, LLC, with 9.0279% or 8.94 million shares worth $7.97 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
